We show how cancer cells can modulate fibroblast function under endocrine treatment by stimulating mesenchymal fibroblast differentiation and amplifying their provision of ERBB ligand signals, which in turn bind to ERBB receptors on cancer cells to drive growth factor medicated proliferation independent of estrogen signaling. This evidence concerns the gene EGFR and cancer.